Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.32 |
| ▸ | UGT8 | Q16880 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26436973 | 0.93 | UGT8 (0.37) | CRBNDDB1GSPT1UGT8 | |
| SCHEMBL30407797 | 0.91 | UGT8 (0.34) | CRBNDDB1GSPT1UGT8 | |
| SCHEMBL26437057 | 0.91 | UGT8 (0.34) | CRBNDDB1GSPT1UGT8 | |
| SCHEMBL30408257 | 0.89 | CCNE1 (0.37) | CRBNDDB1UGT8ACACB | |
| SCHEMBL26437054 | 0.86 | CRBN (0.34) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL30407570 | 0.85 | POLB (0.35) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26087412 | 0.85 | POLB (0.35) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL30407060 | 0.85 | POLB (0.35) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26089701 | 0.85 | POLB (0.35) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26437053 | 0.84 | CRBN (0.34) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | CRBN 1/4885DDB1 322/4885POLB 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.